An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

A Co Antrim woman is on a mission to raise awareness of lung cancer with a fundraising drive after her dad was recently ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

the potential of BDTX-1535 to address the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the ...